Paper35936713
CD44 Glycosylation as a Therapeutic Target in Oncology.
Liao C and 8 others. Front Oncol, 2022. Cited by 39 papers, by iCite.
Cite this record
ConductScience Library. CD44 Glycosylation as a Therapeutic Target in Oncology. Papers, record 35936713. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35936713
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References175
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1730766 | A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. | J Cell Biol | 1992 | https://conductscience.org/library/papers/1730766 | PubMed |
| 2 | 32381431 | Targeting Glycosylation: A New Road for Cancer Drug Discovery. | Trends Cancer | 2020 | https://conductscience.org/library/papers/32381431 | PubMed |
| 3 | 23190608 | miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. | Cell Death Dis | 2012 | https://conductscience.org/library/papers/23190608 | PubMed |
| 4 | 10871609 | Hyaluronan binding by cell surface CD44. | J Biol Chem | 2000 | https://conductscience.org/library/papers/10871609 | PubMed |
| 5 | 25116630 | Terminal sialic acids on CD44 N-glycans can block hyaluronan binding by forming competing intramolecular contacts with arginine sidechains. | Proteins | 2014 | https://conductscience.org/library/papers/25116630 | PubMed |
| 6 | 25960131 | Sp1 transcription factor: A long-standing target in cancer chemotherapy. | Pharmacol Ther | 2015 | https://conductscience.org/library/papers/25960131 | PubMed |
| 7 | 8647947 | CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. | J Clin Invest | 1996 | https://conductscience.org/library/papers/8647947 | PubMed |
| 8 | 10070748 | Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. | J Biomol NMR | 1999 | https://conductscience.org/library/papers/10070748 | PubMed |
| 9 | 27888602 | A Glycovariant of Human CD44 is Characteristically Expressed on Human Mesenchymal Stem Cells. | Stem Cells | 2017 | https://conductscience.org/library/papers/27888602 | PubMed |
| 10 | 26190015 | Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors. | Lung Cancer | 2015 | https://conductscience.org/library/papers/26190015 | PubMed |
| 11 | 34093814 | FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment. | J Cancer | 2021 | https://conductscience.org/library/papers/34093814 | PubMed |
| 12 | 33466384 | FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33466384 | PubMed |
| 13 | 7532175 | Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. | J Cell Biol | 1995 | https://conductscience.org/library/papers/7532175 | PubMed |
| 14 | 31361756 | Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFβ-Hyaluronan-CD44 signalling pathway. | PLoS One | 2019 | https://conductscience.org/library/papers/31361756 | PubMed |
| 15 | 29792572 | GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. | Nucleic Acid Ther | 2018 | https://conductscience.org/library/papers/29792572 | PubMed |
| 16 | 26663681 | Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas. | Cancer Sci | 2016 | https://conductscience.org/library/papers/26663681 | PubMed |
| 17 | 10713114 | Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. | J Biol Chem | 2000 | https://conductscience.org/library/papers/10713114 | PubMed |
| 18 | 34193268 | CD44 fucosylation on bone marrow-derived mesenchymal stem cells enhances homing and promotes enteric nervous system remodeling in diabetic mice. | Cell Biosci | 2021 | https://conductscience.org/library/papers/34193268 | PubMed |
| 19 | 29957956 | CD44-Targeted Polymer-Paclitaxel Conjugates to Control the Spread and Growth of Metastatic Tumors. | Mol Pharm | 2018 | https://conductscience.org/library/papers/29957956 | PubMed |
| 20 | 31778548 | Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. | Blood | 2019 | https://conductscience.org/library/papers/31778548 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42955118 | The status quo and evolution of glycoconjugates for cancer immunotherapy. | Glycoconj J | 2026 | https://conductscience.org/library/papers/42955118 | PubMed |
| 42919624 | Siglec-15 and its glycan ligands in tumor-associated macrophage biology and immunotherapy. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42919624 | PubMed |
| 42855948 | Encoding Cell-Surface Receptor Function Through Glycosylation: Lessons From CD44. | Chembiochem | 2026 | https://conductscience.org/library/papers/42855948 | PubMed |
| 42205480 | Decoding sialidase: physiological roles, pathological pathways, and clinical opportunities. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42205480 | PubMed |
| 42191868 | Mapping galectin-3 ligands in human tear fluid establishes spliceoform-dependent lacritin binding. | Commun Biol | 2026 | https://conductscience.org/library/papers/42191868 | PubMed |
| 41850247 | Spatial tumor evolution panorama of ovarian cancer. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/41850247 | PubMed |
| 41667793 | Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41667793 | PubMed |
| 41465476 | Does Podoplanin (PDPN) Reflect the Involvement of the Immunological System in Coronary Artery Disease Risk? A Single-Center Prospective Analysis. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465476 | PubMed |
| 41440277 | Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein. | Biosensors (Basel) | 2025 | https://conductscience.org/library/papers/41440277 | PubMed |
| 41009438 | CD44 as a Central Integrator of Inflammation and Fibrosis: From Molecular Signaling to Environmental Modulation. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009438 | PubMed |
| 40745508 | Moesin silencing enhances the radiosensitivity of glioblastoma by inhibiting DNA damage repair via CD44/AKT1 signaling pathway. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40745508 | PubMed |
| 40667828 | The Tumour Glyco-Code: Sialylation as a Mediator of Stromal Cell Immunosuppression in the Tumour Microenvironment. | Eur J Immunol | 2025 | https://conductscience.org/library/papers/40667828 | PubMed |
| 40634594 | Combined downregulation of TGF-β1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit. | Cancer Gene Ther | 2025 | https://conductscience.org/library/papers/40634594 | PubMed |
| 40507880 | Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40507880 | PubMed |
| 40221767 | The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/40221767 | PubMed |
| 40114966 | CD44 variant exons induce chemoresistance by modulating cell death pathways. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/40114966 | PubMed |
| 39860065 | Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer. | Life (Basel) | 2025 | https://conductscience.org/library/papers/39860065 | PubMed |
| 39457544 | TGM2-Mediated Autophagy Contributes to the Radio-Resistance of Non-Small Cell Lung Cancer Stem-like Cells. | Biomedicines | 2024 | https://conductscience.org/library/papers/39457544 | PubMed |
| 39333557 | Elevated α-1,2-mannosidase MAN1C1 in glioma stem cells and its implications for immunological changes and prognosis in glioma patients. | Sci Rep | 2024 | https://conductscience.org/library/papers/39333557 | PubMed |
| 38946426 | Glycosylation in the tumor immune response: the bitter side of sweetness. | Acta Biochim Biophys Sin (Shanghai) | 2024 | https://conductscience.org/library/papers/38946426 | PubMed |
Genes62
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35936713
GET https://conductscience.org/api/papers/v1/35936713/references?page=2